Stem Cell Therapeutics Corp. Receives Formal Clearance From the FDA to Proceed With Their Phase IIb Stroke Trial
CALGARY, ALBERTA–(Marketwire – May 15, 2009) – Stem Cell Therapeutics Corp. (”SCT” or “the Company”) (TSX VENTURE:SSS) is pleased to announce the U.S. Food and Drug Administration (”FDA”) has now issued a formal letter to the Company confirming immediate removal of the clinical hold placed on the Phase IIb stroke trial, September 18, 2008. This permits re-initiation of clinical studies for …
[Read the full article here]Related News:
Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial
FDA to lift clinical hold on Stem Cell Therapeutics' phase-IIb stroke trial
Stem Cell Therapeutics Corp. Announces Top-Line Results for the Modified REGENESIS Phase IIb Stroke Trial